Bayer Sells Unit to Boston Scientific; Focuses on Radiology, Diabetes Growth
Bayer HealthCare will sell its Interventional device business to Boston Scientific for $415 million.
According to Dr. Olivier Brandicourt, CEO of Bayer HealthCare AG, “With this sale, our Medical Care division can concentrate on innovation and growth in Radiology and Diabetes Care where we already have a strong presence.”
The sale will include the AngioJet™ (thrombectomy) and Jetstream™ (atherectomy) systems, and the Fetch™2 Aspiration Catheter used in cardiology, radiology and peripheral vascular procedures.
The transaction is expected to close in the second half of 2014.
In the most general of terms, interventional devices aid in minimally invasive procedures, usually involving blood vessels, which can be done instead of actual surgery.
Read the Bayer press release